Galectin Therapeutics said it reached alignment with the FDA in a recent in-person Type C meeting on the primary endpoint and regulatory path forward for Belapectin. The update reduces regulatory uncertainty for the clinical-stage biotech's lead program and supports continued development progress. The news is positive for the stock, though it is still an early-stage regulatory milestone rather than an approval.
Galectin Therapeutics said it reached alignment with the FDA in a recent in-person Type C meeting on the primary endpoint and regulatory path forward for Belapectin. The update reduces regulatory uncertainty for the clinical-stage biotech's lead program and supports continued development progress. The news is positive for the stock, though it is still an early-stage regulatory milestone rather than an approval.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
